Cerenkov luminescence imaging of medical isotopes

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1123-1130

  Ruggiero, Alessandro ^a   Holland, Jason P ^a   Lewis, Jason S ^a   Grimm, Jan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

124I; 131I; 18F; 225Ac; 64Cu; 89Zr; Cerenkov; Imaging technology; J591; Monoclonal antibodies; Optical imaging; PET; Prostate specific membrane antigen (PSMA); Radioimmunoconjugate

Indexed keywords

DESFERRIOXAMINE B MONOCLONAL ANTIBODY J591 ZR 89; FLUORINE 18; IODINE 124; ISOTOPE; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM; DEFEROXAMINE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN LNCAP; CERENKOV LUMINESCENCE IMAGING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNE DEFICIENCY; IN VIVO STUDY; INFRARED RADIATION; ISOTOPE LABELING; LIGHT INTENSITY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR; ALPHA RADIATION; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; ELECTRON; FEMALE; HUMAN; IMMUNOLOGY; LUMINESCENCE; METABOLISM; NEOPLASM; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; VALIDATION STUDY;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; BETA PARTICLES; DEFEROXAMINE; DIAGNOSTIC IMAGING; DRUG EVALUATION, PRECLINICAL; ELECTRONS; FEMALE; HUMANS; LUMINESCENCE; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 77954963053     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076521     Document Type: Article

References (41)

1. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580-589.
2. Pichler BJ, Kolb A, Nagele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-336.
3. Kirsch DG, Dinulescu DM, Miller JB, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007;13:992-997.
4. Grimm J, Kirsch DG, Windsor SD, et al. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci. 2005;102:14404-14409.
5. Cerenkov PA. Visible emission of clean liquids by action of γ-radiation. C R Dokl Akad Nauk SSSR. 1934;2:451-454.
6. Jelley JV. Cerenkov radiation and its applications. Br J Appl Phys. 1955;6:227-232.
7. Ross HH. Measurement of β-emitting nuclides using Cerenkov radiation. Anal Chem. 1969;41:1260-1265.
8. 32P Cerenkov counting. Anal Biochem. 1971;42:360-362.
9. 32P scintillating plastic vials. Appl Radiat Isot. 1987;38:311-312.
10. Hansen BS. Improved method for assaying pyrophosphate exchange measuring Cerenkov radiation. Anal Biochem. 1980;109:12-17.
11. Berger SL. The use of Cerenkov radiation for monitoring reactions performed in minute volumes: examples from recombinant DNA technology. Anal Biochem. 1984;136:515-519.
12. Miyata M, Tomita H, Watanabe K, Kawarabayshi J, Iguchi T. Development of TOF-PET using Cherenkov radiation. J Nucl Sci Technol. 2006;43:339-343.
13. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, Silva MD. Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Phys Med Biol. 2009;54:N355-N365.
14. Cho JS, Taschereau R, Olma S, et al. Cerenkov radiation imaging as a method for quantitative measurements of beta particles in a microfluidic chip. Phys Med Biol. 2009;54:6757-6771.
15. Spinelli AE, D'Ambrosio D, Calderan L, Marengo M, Sbarbati A, Boschi F. Cerenkov radiation allows in vivo optical imaging of positron emitting radiotracers. Phys Med Biol. 2010;55:483-495.
16. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010;9:1-20.
17. Welch MJ, Redvanly CS, Editors. Handbook of Radiopharmaceuticals: Radiochemistry and Applications. New York, NY: Wiley; 2003.
18. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
19. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
20. Sheh Y, Koziorowski J, Balatoni J, Lom C, Dahl JR, Finn RD. Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target. Radiochim Acta. 2000;88:169-173.
21. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
22. Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60:1371-1382.
23. Kim JS, Lee JS, Im KC, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527-1535.
24. 89Zr-DFO-trastuzumab. PLoS One. 2010;5:e8859.
25. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
26. Levin CS, Hoffman EJ. Calculation of positron range and its effects on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol. 1999;44:781-799.
27. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Philadelphia, PA: Saunders; 2003.
28. McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ. 2002;9:593-594.
29. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
30. Singh Jaggi J, Henke E, Seshan SV, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One. 2007;2:e267.
31. Ballangrud ÅM, Yang W-H, Palm S, et al. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489-4497.
32. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor endothelium. Cancer Res. 1997;57:3629-3634.
33. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055-4060.
34. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
35. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. 2003;44:610-617.
36. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100.
37. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
38. Perk LR, Visser OJ, Stigter-van Walsum M, et al. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337-1345.
39. 89Zrlabeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
40. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-131.
41. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.